# DESCRIPTION

## TECHNICAL FIELD

- introduce RNA virus replication control

## TECHNOLOGICAL BACKGROUND

- describe gene therapy vectors
- describe RNA virus limitations
- introduce aptazymes
- describe HIV protease

## SUMMARY OF THE INVENTION

- introduce conditional protease approach
- describe regulatable switch
- introduce ON-switch
- describe intramolecular insertion site
- introduce OFF-switch
- describe intermolecular insertion site
- describe protease inhibitor
- describe viral polymerase activity
- introduce single-stranded RNA virus
- describe modified genome
- describe polynucleotide sequence
- describe essential protein
- describe protease and cleavage site
- describe heterologous protein
- describe oncolytic virus
- describe VSV
- describe glycoprotein GP
- describe protease regulation

## DETAILED DESCRIPTION

- define general embodiments
- clarify singular and plural forms
- define homologue
- define corresponding to amino acid position
- define fusion protein
- define polyprotein
- define genomic RNA
- define gene
- define nucleic acid
- define ribonucleic acid
- define upstream and downstream
- define coding strand
- define non-coding strand
- define vector
- define encode
- define heterologous polypeptide
- define therapeutic protein
- define cytokine
- define expression
- define reporter gene

### Conditional Regulation for an RNA Virus

- define single-stranded RNA virus with modified genome
- describe ON-switch aspect with protease and cleavage site
- describe OFF-switch aspect with fusion protein and cleavage site
- specify RNA viruses suitable for the invention
- identify at least one protein essential for viral transcription and/or replication
- describe RdRp complex in VSV
- specify order Mononegavirales and families thereof
- identify polymerase cofactor, polymerase, and nucleocapsid protein
- describe functional equivalent of P-protein
- specify L-protein, P-protein, and N-protein in various families
- describe regulation of viral transcription and/or replication by protease
- define cleavage site for said protease
- describe autocatalytic protease or protease acting as autocatalytic protease
- specify protease framed by cleavage site on either side
- describe ON-switch with insert at intramolecular insertion site
- describe protease or autocatalytic protease from various sources
- specify protease inhibitor and its properties
- describe HIV protease inhibitors and human protease inhibitors
- specify single-chain dimer of protease and its properties
- describe oncolytic virus and its properties

### ON-Switch

- define modified genome of single-stranded RNA virus
- describe insert at intramolecular insertion site
- explain activity assessment of modified protein
- describe expression of modified protein
- outline proteolytic cleavage and inactivation
- describe virus activity in presence/absence of protease inhibitor
- introduce heterologous protein expression
- describe specific embodiment with HIV protease dimer
- outline insert with protease and cleavage sites
- describe RNA virus and essential proteins
- explain codon usage optimization
- describe doubling of protease module
- introduce suitable insertion sites for P-protein and L-protein
- outline environmental safety element and therapeutic use

### OFF-Switch

- define single-stranded RNA virus
- describe fusion protein with protease and cleavage site
- explain inactivation of protein essential for viral transcription/replication
- describe proteolytic cleavage and activation of protein
- introduce specific inhibitor of protease
- describe inactive fusion protein without proteolytic cleavage
- explain replacement of intergenic region with protease and cleavage site
- describe loss of protease leading to inactive fusion protein
- introduce gene shuffling for adjacent proteins
- describe alternative embodiment with heterologous protein
- explain autocatalytic protease with two cleavage sites
- describe preferred embodiments of protease and protein essential for viral transcription/replication
- introduce modified genome of virus with polynucleotide sequence
- describe optional linkers between protease and protein essential for viral transcription/replication
- explain preferred embodiments of fusion protein
- describe use of single-stranded RNA virus in therapy, particularly cancer therapy

### Conditional Expression of a Heterologous Protein

- describe modified genome of virus with polynucleotide sequence
- introduce insert at intramolecular insertion site with cleavage site and protease
- explain conditional expression of heterologous protein
- describe ON-switch and OFF-switch embodiments
- introduce therapeutic protein, reporter, or tumor antigen as heterologous protein
- describe oncolytic virus, particularly VSV
- explain heterologous protein as therapeutic protein with immune-modulatory or cell death modulatory function
- describe tumor antigen, including tumor-specific and tumor-associated antigens
- describe use of RNA virus in therapy, particularly cancer therapy

### Therapeutic Use

- describe therapeutic use of modified RNA virus
- specify cancer therapy and administration routes
- list suitable protease inhibitors and their administration

### L-Protein Insertion Site

- introduce recombinant VSV L-protein with insert
- define intramolecular insertion site and its properties
- describe insert properties and its effect on L-protein activity
- specify examples of inserts and their characteristics

### In Vitro Method

- describe in vitro method for controlling RNA virus replication
- introduce modified genome of RNA virus
- describe protease and cleavage site
- outline method for controlling viral transcription and/or replication
- specify in vitro method
- list preferred proteases
- list protease inhibitors
- introduce single-stranded RNA virus
- describe modified genome of single-stranded RNA virus
- outline items 1-9
- describe single-stranded RNA virus with modified genome
- outline items 1-11
- describe single-stranded RNA virus with fusion protein
- outline items 1-13
- describe single-stranded RNA virus with fusion protein and linker
- introduce RNA virus with modified genome for heterologous protein expression
- describe RNA virus with modified genome for therapeutic protein expression
- outline uses of single-stranded RNA virus and RNA virus

## EXAMPLES

### P-Protein

- construct P-protein with linked-dimer protease
- test functionality of P-protein-protease construct

### L-Protein

- introduce HIV protease dimer into VSV L protein

### VSV Vectors

- generate VSV vectors with protease insert

### Cell Lines

- describe cell lines used in experiments

### In Silico Experiments

- perform structure visualization and molecular modeling

### Replication Kinetic

- measure replication kinetics of VSV variants

### Dose Response

- determine dose response of VSV variants to amprenavir

### TCID50 Assay

- introduce TCID50 assay
- describe virus titration method
- explain cytopathic effect
- count infected wells
- calculate TCID50 values
- introduce in vitro cytotoxicity assay
- describe plaque assay
- introduce immunoblotting
- describe SDS-PAGE
- transfer proteins to nitrocellulose membrane
- block membrane with skim milk and Tween 20
- incubate with mCherry-specific antibody
- wash and incubate with peroxidase-conjugated antibody
- develop blots with enhanced chemiluminescence
- introduce transfections
- describe transfection of L-mCherry expression plasmids
- introduce animal experiments
- describe stereotactic mouse brain injections
- introduce image analysis
- describe fluorescence microscope analysis
- introduce statistical analysis
- describe statistical significance determination
- introduce TCID50 assay
- perform dose response study
- generate tandem protease-regulated ON-switch
- confirm genomic integrity
- test genomic integrity of VSV-P-mWasabi-L-mCherry
- generate double ON switch regulated VSV variant
- optimize codon usage of flexible linkers and protease dimer
- generate protease-regulated OFF-switch
- test genomic integrity of VSV-GFP-Prot-L
- perform dose response study for VSV-GFP-Prot-L
- test response to different protease inhibitors
- determine single step replication kinetic
- introduce TCID50 assay
- describe Example 11: VSV-Pprot-Luc regulation
- describe bioluminescence imaging results
- describe Example 12: VSV-L-prot regulation
- describe tumor growth and survival benefits
- describe Example 13: VSV-Prot-Off regulation
- describe tumor regression and neurotoxicity
- describe Example 14: VSV-Prot-Off regulation
- describe immunofluorescence analysis
- describe Example 15: VSV-GP-IL12-Prot-Off regulation
- describe soluble IL12 expression
- describe Example 16: VSV-GP-IL12-Prot-Off regulation
- describe soluble IL12 expression with atazanavir
- describe Example 17: VSV-GP-Prot-Off replication kinetics
- describe Example 18: membrane-bound IL12 expression
- describe regulation of membrane-bound IL12 expression

